Medifile: PNEUMOCOCCAL VACCINE FOR INFANTS AND TODDLERS
Abstract
The South African launch of Prevenar®, a new polyvalent conjugate vaccine, has resulted in many questions being posed by health care providers and parents alike. Without a government policy on the role of this vaccine and considering its high cost, there is much debate on its place in therapy, cost benefit and long term epidemiological effect. This article provides an overview of the vaccine, its known advantages, potential disadvantages, place in therapy and administration.
Section
Regulars
By submitting manuscripts to SAFP, authors of original articles are assigning copyright to the South African Academy of Family Physicians. Copyright of review articles are assigned to the Publisher, Medpharm Publications (Pty) Ltd, unless otherwise specified. Authors may use their own work after publication without written permission, provided they acknowledge the original source. Individuals and academic institutions may freely copy and distribute articles published in SAFP for educational and research purposes without obtaining permission.
